Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04376840|
Recruitment Status : Recruiting
First Posted : May 6, 2020
Last Update Posted : November 30, 2020
Studies performed after coronavirus epidemics (severe acute respiratory syndrome coronavirus, SARS-CoV and Middle East respiratory syndrome coronavirus, MERS-CoV) have shown a long-term impact on respiratory morbidity, musculoskeletal and psycho-social repercussions.
Patients with SARS-CoV pneumonia had fibrotic pulmonary sequelae at 45 days (lower DLCO in 27.3% of cases and radiological lesions in 21.5% of cases). In the MERS-CoV pneumonia study, patients had radiological sequelae in 33% of cases and the 12-month evaluation showed persistence of radiological abnormalities in 23.7% of the cases despite an improvement in respiratory function.
Clinical presentation and therapeutic management of severe SARS-CoV-2 infection are in part similar to those induced by SARS-CoV and MERS-CoV. Long-term respiratory complications are therefore expected.
|Condition or disease||Intervention/treatment||Phase|
|Severe SARS-CoV2 Pneumonia||Other: Blood sample and data record||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||270 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia|
|Actual Study Start Date :||May 28, 2020|
|Estimated Primary Completion Date :||January 28, 2022|
|Estimated Study Completion Date :||October 28, 2022|
Experimental: adults with severe SARS-CoV2 pneumonia
adult with severe SARS-CoV2 pneumonia
Other: Blood sample and data record
Blood sample and data record
- medium-term respiratory complications [ Time Frame: 3 months ]Interstitial lung disease diagnosed with a thoracic CT-scan
- long-term respiratory complications [ Time Frame: 12 months ]Interstitial lung disease diagnosed with a thoracic CT-scan
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04376840
|Contact: Jeanne-Marie PEROTIN-COLLARD||03 10 73 67 firstname.lastname@example.org|
|Contact: Jeanne-Marie PEROTIN-COLLARD 03 10 73 67 63 ext 0033 email@example.com|